Stryker Co. (NYSE:SYK) is Davis Rea LTD.’s 8th Largest Position

Davis Rea LTD. decreased its stake in shares of Stryker Co. (NYSE:SYK) by 9.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,301 shares of the medical technology company’s stock after selling 3,323 shares during the period. Stryker comprises about 5.5% of Davis Rea LTD.’s investment portfolio, making the stock its 8th biggest holding. Davis Rea LTD.’s holdings in Stryker were worth $10,935,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in SYK. Parnassus Investments LLC bought a new stake in Stryker during the 3rd quarter valued at $762,798,000. Proficio Capital Partners LLC lifted its holdings in shares of Stryker by 52,520.8% during the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock valued at $214,660,000 after purchasing an additional 595,061 shares during the last quarter. RTW Investments LP acquired a new position in shares of Stryker in the third quarter worth about $143,392,000. State Street Corp grew its position in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares in the last quarter. Finally, FMR LLC raised its position in Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company’s stock valued at $2,639,725,000 after buying an additional 215,782 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Stryker Stock Down 0.7 %

Shares of NYSE:SYK opened at $389.10 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The company has a market cap of $148.47 billion, a PE ratio of 50.14, a P/E/G ratio of 2.93 and a beta of 0.96. The stock’s 50-day moving average is $380.06 and its 200 day moving average is $370.50. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the company posted $3.46 EPS. Sell-side analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Needham & Company LLC reissued a “buy” rating and issued a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Argus set a $450.00 target price on Stryker in a research note on Monday, February 3rd. Citigroup reaffirmed a “buy” rating and issued a $450.00 price target on shares of Stryker in a research note on Wednesday. Finally, The Goldman Sachs Group raised their price objective on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.